Merck Sharp + Dohme Corp.

Pharmacopeia Inc.

Rui Zhang

Guoqing Li

Joseph A Kozlowski

Yongxin Han

Alexander Pasternak

Yong Zhang

Xianhai Huang

Barbara A Pio

Wensheng Yu

Songnian Lin

Emma R Parmee

Jongwon Lim

Dong Xiao

Shuwen He

Liangqin Guo

Subharekha Raghavan

Jianmin Fu

Li Xiao

Xavier Fradera

Cameron James Smith

Shouwu Miao

Dane James Clausen

Brian T Campbell

Yi-Heng Chen

Feroze Ujjainwalla

David L Sloman

Ping Liu

Vidyadhar Madhav Paradkar

John S Debenham

Helen Y Chen

Nunzio Sciammetta

Harry R Chobanian

Ping Chen

Yan Guo

Richard Berger

Christopher W Plummer

Timothy A Blizzard

Jiayi Xu

John E Stelmach

Joie Garfunkle

Alan Whitehead

Haiqun Tang

Hong Li

Libo Xu

Sunita V Dewnani

Theodore A Martinot

Hong-Dong Li

Timothy Allen Blizzard

Michelle Lee Morris

Feng Ye

Zhiqiang Guo

Raphaelle Berger

Bart Harper

Zhiyong Hu

Ming Wang

Ruiyan Liu

Chongwu Zhang

Cangming Yang

Gang Ji

Falong Jiang

Ray Anthony James

Andreas Verras

Candido Gude

Michael J Ohlmeyer

Zack Zhiqiang Guo

W Michael Seganish

Byron Dubois

Roman Kats-Kagan

James Robert Merritt

Jinqi Liu

Marc Brescia

Jennifer Hanisak

Michael Miller

Raphelle Berger

John Stelmach

Michael W Seganish

Disclosed herein are compounds of formula (I) which are inhibitors of an IDO enzyme: (I). Also disclosed herein are uses of the compounds in the potential treatment or prevention of an IDO-associated disease or disorder. Also disclosed herein are compositions comprising these compounds. Further disclosed herein are uses of the compositions in the potential treatment or prevention of an IDO-associated disease or disorder.

Substituted piperazine amide compounds as indoleamine 2,3-dioxygenase (IDO) inhibitors

Substituted pyrazole compounds as indoleamine 2,3-dioxygenase inhibitors

The invention provides compounds of the Formula (I) or a pharmaceutically acceptable salts thereof, wherein X, Y, Z, R, R, R, R, and the subscripts m, p, and q are as described herein. The compounds or their pharmaceutically acceptable salts can modulate the body's production of cyclic guanosine monophosphate ('cGMP'), and are generally suitable for the therapy and prophylaxis of diseases which are associated with a disturbed cGMP balance. The invention also provides pharmaceutical compositions which comprise compounds of Formula (I) or pharmaceutically acceptable salts thereof. The invention also relates to methods for use of the compounds or their pharmaceutically acceptable salts in the therapy and prophylaxis of the abovementioned diseases and for preparing pharmaceuticals for this purpose.

Soluble guanylate cyclase stimulators

The compounds of Formula I act as MGAT2 inhibitors and can be useful in preventing, treating or acting as a remedial agent for hyperlipidemia, diabetes mellitus and obesity. 

Isoquinoline derivatives as MGAT2 inhibitors

The present invention relates to inhibitors of IRAK4 of Formula (I) and provides compositions comprising such inhibitors, as well as methods therewith for treating IRAK4-mediated or -associated conditions or diseases.

Inhibitors of IRAK4 activity

Novel pyridine-2-carboxamide derivatives of formula I: and pharmaceutically acceptable salts thereof are disclosed as useful for treating or preventing type 2 diabetes and similar conditions. The compounds are effective as glucokinase activating agents. Pharmaceutical compositions and methods of treatment are also included. 

Glucokinase activator compounds, compositions containing such compounds, and methods of treatment

Compounds of the formula are disclosed. The compounds are CCR1 antagonists which are useful for the treatment and prevention of inflammatory and autoimmune diseases. Other embodiments are also disclosed.

Ortho pyrrolidine, benzyl-substituted heterocycle CCR1 antagonists for autoimmune diseases and inflammation

Growing community of inventors

Plainsboro, NJ, United States of America

Rui Zhang